Navigation Links
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
Date:5/5/2008

Q8003IR Met Primary Endpoints; Demonstrated Strong Reduction of Pain Intensity

SYDNEY, Australia and BEDMINSTER, N.J., May 5

/PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today initial Phase 3 efficacy results for Q8003IR, an immediate release dual-opioid product intended for the acute management of moderate to severe pain.

"Initial Phase 3 efficacy data demonstrated statistically significant analgesic activity at all doses tested and reinforces the potential clinical benefit and commercial value of QRxPharma's lead dual-opioid product," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We are pleased with this study outcome and believe that it demonstrates that the Company remains on target to complete clinical testing for Q8003IR, submit a New Drug Application (NDA) in 2009 and achieve its goal of product launch in 2010."

The double-blind, placebo-controlled study was designed to compare the efficacy and safety of four different dosage regimens of Q8003IR, a fixed ratio morphine/oxycodone combination. 256 patients with moderate to severe pain following surgery (bunionectomy) completed the trial, and it was conducted at six US clinical research sites. The primary efficacy analysis compared the change in pain intensity scores over the 48 hr dosing period (SPID48) in patients receiving Q8003IR vs. placebo.

Among all patients receiving Q8003IR, approximately 50% reported good to excellent global improvement (vs. 13% for placebo) and demonstrated a strong dose-response effect (p<0.001) in reducing pain intensity scores [i.e. the sum of pain intensity difference over 48 hours relative to the first dose (SPID48)] and other measures of analgesic effect. Per treatment group, median doses received every 4 hours ranged from 3mg/2 mg to 9mg/6 mg of morphine/oxycodone.

The data further demonstrate that Q8003IR was generally well tolerated, with a low rate of patient withdrawal (2% to 12% depending on dose vs. 2% for placebo). In addition, there was minimal somnolence (2% to 8%) and changes to respiratory parameters (respiration rate, oxygen saturation) with no incidences of euphoria reported. Nausea and vomiting (usually mild) were the most common adverse events. Further analysis of side effect profiles is underway and these data will be available by late May 2008.

Q8003IR is a patent-protected combination of morphine and oxycodone which has been clinically shown to provide synergistic effects on pain relief with a significant reduction of total opioid dose and side effects.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, successfully completed a Phase 3 study and met primary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: http://www.QRxPharma.com


'/>"/>
SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Immunosyn Corporation Releases SF-1019 Study Results
5. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
6. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
10. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Global ... industry including definitions, classifications, applications and industry chain structure. ... market including development history, competitive landscape analysis, and major ... ... spread across 105 pages providing 10 company profiles and ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Supplies - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... ... 2017 , ... Empower Brokerage, located in Southlake, Texas, intends ... , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program to ... teach how to maximize their sales efforts, as well as how to best ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment ... more public health departments have been awarded national accreditation through the Public ... into the expanding network of communities across the nation whose health departments meet ...
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that ... brush their teeth the minimum two times a day that dentists recommend. The ramifications of ... million hours of school and adults missing 164 million hours of work each year due ...
Breaking Medicine News(10 mins):